Translation and Commercialization of a QSOX1-inhibitory Antibody Targeting the Tumor Microenvironment in Breast Cancer

Project Information

CONQR

Grant agreement ID: 825076

DOI

10.3030/825076

Project closed

EC signature date 12 November 2018

Start date 1 December 2018

End date 31 May 2020

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 149 998,00

EU contribution

€ 149 998,00

Coordinated by

WEIZMANN INSTITUTE OF SCIENCE
Israel

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models

Author(s): Tal Feldman, Iris Grossman-Haham, Yoav Elkis, Patrick Vilela, Neta Moskovits, Iris Barshack, Tomer M. Salame, Deborah Fass, Tal Ilani
Published in: Oncotarget, Issue 11/4, 2020, Page(s) 386-398, ISSN 1949-2553
Publisher: Impact Journals
DOI: 10.18632/oncotarget.27438

Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces

Author(s): Shira Warszawski, Aliza Borenstein Katz, Rosalie Lipsh, Lev Khmelnitsky, Gili Ben Nissan, Gabriel Javitt, Orly Dym, Tamar Unger, Orli Knop, Shira Albeck, Ron Diskin, Deborah Fass, Michal Sharon, Sarel J. Fleishman
Published in: PLOS Computational Biology, Issue 15/8, 2019, Page(s) e1007207, ISSN 1553-7358
Publisher: PLoS
DOI: 10.1371/journal.pcbi.1007207